← Back to Search

Genetic Testing

Pharmacogenomic Testing for High Cholesterol

N/A

Waitlist Available

Led By Deepak Voora, MD

Research Sponsored by VA Office of Research and Development

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Aged 40-75 years

Diagnosed with diabetes mellitus or cardiovascular disease (coronary, cerebral, or peripheral artery disease)

Must not have

Active prescription for PCSK9 inhibitor

Liver cirrhosis

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 15-months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to address the issue of high-risk cardiovascular disease patients not accepting or sticking to statin medication, even though it is cost-effective in reducing cholesterol levels and CVD risk. The main barriers

Who is the study for?

This trial is for individuals with high cholesterol who are at risk for cardiovascular disease (CVD) but may be hesitant to take statins due to concerns about their effectiveness or potential side effects. Participants should not currently be on statin therapy.

What is being tested?

The study tests whether genetic testing can help predict the benefits and risks of taking statins, potentially improving patient acceptance and adherence by personalizing treatment plans based on individual genetic profiles.

What are the potential side effects?

While specific side effects are not detailed here, common ones associated with statins include muscle pain, digestive problems, increased blood sugar levels, and neurological symptoms like memory loss or confusion.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 40 and 75 years old.

Select...

I have been diagnosed with diabetes or heart/blood vessel disease.

Select...

I currently have an active prescription from the VA.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am currently prescribed a PCSK9 inhibitor medication.

Select...

I have liver cirrhosis.

Select...

I have had rhabdomyolysis in the past.

Select...

I am currently receiving treatment for a cancer that is not skin cancer.

Select...

I have not been under palliative or hospice care in the last year.

Select...

I have had a stem cell or liver transplant.

Select...

My kidneys are in the final stage of failure.

Select...

I know my SLCO1B1 genetic test results.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 15-months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~15-months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 15-months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in low density lipoprotein cholesterol

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Genetic testing armExperimental Treatment1 Intervention

The intervention involves: genetic testing; interpretation; and prior to and shortly following an upcoming appointment, communication to patients and providers about the patients' predicted statin efficacy and toxicity, genetic risk for CVD, and individualized recommended statin type/dose.

Group II: ControlActive Control1 Intervention

The control condition involves receipt of a report highlighting the risk of cardiovascular disease and benefits of statins (without genetic test results).

0 / 11Eligibility criteria met